| P&L Statement | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 5729 | 6644 | 5664 | 5872 |
| Cost of Material Consumed | 5342 | 5669 | 4737 | 4918 |
| Change in Inventory | -229 | 62 | 143 | -4 |
| Gross Margins | 10.75 | 13.74 | 13.84 | 16.31 |
| Employee Benefit Expenses | 1459 | 1283 | 699 | 908 |
| Other Expenses | 1502 | 1051 | 731 | 711 |
| EBITDA | -2345 | -1421 | -646 | -661 |
| OPM | -40.93 | -21.39 | -11.41 | -11.26 |
| Other Income | -1185 | -2866 | 931 | -181 |
| Finance Cost | 258 | 666 | 728 | 506 |
| D&A | 159 | 243 | 216 | 169 |
| EBIT | -2504 | -1664 | -862 | -830 |
| EBIT Margins | -43.71 | -25.05 | -15.22 | -14.13 |
| PBT | -3977 | -5196 | -2522 | -1517 |
| PBT Margins | -69.42 | -78.21 | -44.53 | -25.83 |
| Tax | 22 | 15 | 11 | 55 |
| PAT | -3999 | -5211 | -2533 | -1572 |
| NPM | -69.8 | -78.43 | -44.72 | -26.77 |
| EPS | -6.51 | -8.48 | -3.9 | -2.26 |
| Financial Ratios | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating Profit Margin | -40.93 | -21.39 | -11.41 | -11.26 |
| Net Profit Margin | -69.8 | -78.43 | -44.72 | -26.77 |
| Earning Per Share (Diluted) | -6.51 | -8.48 | -3.9 | -2.26 |
| Assets | 2023 | 2024 | 2025 |
|---|---|---|---|
| Fixed Assets | 912 | 734 | 662 |
| CWIP | 4 | 3.6 | 14 |
| Investments | 342 | 329 | 179 |
| Trade Receivables | 905 | 706 | 670 |
| Inventory | 688 | 556 | 554 |
| Other Assets | 5405 | 6061.4 | 4898 |
| Total Assets | 8256 | 8390 | 6977 |
| Liabilities | 2023 | 2024 | 2025 |
|---|---|---|---|
| Share Capital | 614.2 | 614.2 | 614.2 |
| FV | 1 | 1 | 1 |
| Reserves | 1823 | 1938 | 2577 |
| Borrowings | 4120 | 4098 | 2034 |
| Trade Payables | 413 | 413 | 426.6 |
| Other Liabilities | 1285.8 | 1291.4 | 1244.5 |
| Total Liabilities | 8256 | 8390 | 6977 |
| Cash-Flow Statement | 2023 | 2024 | 2025 |
|---|---|---|---|
| PBT | -5196 | -2522 | -1517 |
| OPBWC | -637 | -214 | -36 |
| Change in Receivables | -112 | 30 | -56 |
| Change in Inventories | 73 | 133 | 1.6 |
| Change in Payables | -45 | -0.5 | 8 |
| Other Changes | 39 | 26.5 | -93.6 |
| Working Capital Change | -45 | 189 | -140 |
| Cash Generated From Operations | -682 | -25 | -176 |
| Tax | -62 | -36 | -47 |
| Cash Flow From Operations | -744 | -61 | -223 |
| Purchase of PPE | -95 | -72 | -80.6 |
| Sale of PPE | 8 | 10 | 22 |
| Cash Flow From Investment | -72 | -1261 | 775 |
| Borrowing | 652 | -231 | -2187 |
| Dividend | -23 | -29.5 | -28 |
| Equity | 548 | 2000 | 1808.8 |
| Others From Financing | -324 | -282.5 | -353.8 |
| Cash Flow from Financing | 853 | 1457 | -760 |
| Net Cash Generated | 37 | 135 | -208 |
| Cash at the Start | 157 | 192 | 327 |
| Cash at the End | 194 | 327 | 119 |
PharmEasy, operated by API Holdings Limited, is one of India’s leading digital healthcare platforms, offering end-to-end services such as online medicine delivery, diagnostic test bookings, teleconsultations, and health products. The company has played a significant role in transforming India’s healthcare retail landscape by making medical services more accessible, affordable, and convenient. With a strong presence across major cities and Tier-II/Tier-III markets, PharmEasy has built an extensive network of pharmacies, diagnostic centers, and healthcare partners. Its technology-driven model enables seamless order processing, last-mile delivery, and digitized medical records, enhancing user experience and customer retention.
From a business standpoint, PharmEasy has pursued aggressive expansion through strategic acquisitions and integration of healthcare services. Its notable acquisitions include Medlife and Thyrocare Technologies, allowing the company to strengthen its diagnostic and pharmacy ecosystem under one umbrella. PharmEasy’s platform leverages AI, data analytics, and supply-chain optimization to reduce operational costs, improve fulfillment efficiency, and provide personalized recommendations. Despite facing challenges such as competition from other e-pharmacy players, regulatory uncertainties, and high customer acquisition costs, the company continues to refine its revenue model through subscription plans, diagnostic services, B2B distribution, and digital healthcare solutions for hospitals and clinics. These efforts support its long-term vision to become a comprehensive digital health infrastructure provider.
In the unlisted shares market, PharmEasy attracts strong investor interest due to its scale, brand equity, and leadership position in India’s rapidly growing digital health sector. While the company has navigated valuation corrections and financial restructuring in recent years, its long-term potential remains tied to rising digital adoption, increased preference for home healthcare services, and ongoing industry formalization. Investors considering PharmEasy’s unlisted shares should factor in the competitive landscape, regulatory developments, and the company’s path toward profitability. Even with liquidity constraints typical of unlisted markets, PharmEasy remains a high-potential opportunity for investors who believe in the future of digital healthcare in India.
Q:1 How do I confirm my booking for PharmEasy Unlisted Shares?Answer: You can confirm your booking by contacting us and agreeing to the trading price for the PharmEasy Unlisted Shares you wish to purchase.
Q:2 What documents do I need to provide for the purchase of PharmEasy Unlisted Shares?Answer: You need to provide your client master report (CMR), PAN Card, and a Cancelled Cheque if you are not transferring funds from the bank account mentioned in the CMR.These documents are required for KYC compliance as per SEBI regulations.
Q:3 How can I obtain my client master report (CMR)?
Answer: You can request your client master report from your broker if you do not have it available.
Q:4 What payment methods are accepted for purchasing PharmEasy Unlisted Shares?Answer: Payments can be made via RTGS, NEFT, IMPS, or cheque transfer.Please note that cash deposits are not accepted.
Q:5 Will I receive the bank details for the fund transfer?
Answer: Yes, we will provide you with the necessary bank details for transferring the funds after you confirm your booking.
Q:6 Is there a specific timeline for the payment process?Answer: While specific timelines may vary, it's important to complete the payment promptly after confirming your booking to ensure the transaction is processed smoothly.
Q:7 Can I transfer funds from a different bank account than the one mentioned in my CMR?Answer: If you are transferring funds from a different bank account, you will need to provide a Cancelled Cheque along with your other KYC documents.
Q:8 What happens if I do not provide the required KYC documents?Answer: If the required KYC documents are not provided, your transaction may be delayed or may not be processed in accordance with SEBI regulations.